Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03886493 Not yet recruiting - Prostate Cancer Clinical Trials

Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer

Start date: April 2019
Phase: Phase 2
Study type: Interventional

This is a single-center, single arm, open-label phase II study evaluating the safety, anti-tumor effect, and immunogenicity of neoadjuvant Dupixent given prior to radical prostatectomy.

NCT ID: NCT03878524 Not yet recruiting - Breast Cancer Clinical Trials

A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia

SMMART
Start date: March 14, 2019
Phase: Phase 1
Study type: Interventional

This Phase Ib study assesses feasibility and safety of a personalized medicine approach that utilizes a series of clinical study analytics to characterize the cancer based on DNA mutations, RNA and protein expression, physical and molecular architecture of the cancer tissue, and function of cells. This clinical study analytics will be considered by a tumor board to select therapeutic drug combinations tailored to each individual. The chosen drugs are intended to optimally inhibit and/or perturb biological pathways promoting the growth and/or survival of an individual participant's cancer. Serial biopsies and analytics will allow for the therapy to adapt as the patient's cancer adapts to biological perturbation. The study will include patients with advanced cancer of the breast (BCa), prostate (PCa), or pancreas (PanCa), or those with refractory acute myelogenous leukemia (AML).

NCT ID: NCT03869216 Not yet recruiting - Prostate Cancer Clinical Trials

Fostering Shared Decision-making About Prostate Cancer Screening Among Clinicians and African American Men

Start date: September 1, 2019
Phase: N/A
Study type: Interventional

This behavioral clinical trial assesses the efficacy of a dual-pronged intervention for Primary Care Providers and African American males to increase shared decision making about PSA-based screening for prostate cancer. Half of participants will receive a multimedia educational intervention, while the other half will receive usual care.

NCT ID: NCT03861676 Not yet recruiting - Prostate Cancer Clinical Trials

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

Start date: March 2019
Phase: Early Phase 1
Study type: Interventional

The Principal Investigator's (PI) working hypothesis is that the PI can utilize the high predictive value of 18F-DCFPyl PSMA to identify clinically significant tumors in patients who will undergo brachytherapy, as well as areas which are uninvolved or contain only clinically insignificant disease. In the PI's clinical trial, the uninvolved regions (as defined by combined PET-MR-biopsy data) will not be targeted and receive only fall-off dose, which we have shown to be associated with reductions in toxicity.

NCT ID: NCT03861507 Not yet recruiting - Prostate Cancer Clinical Trials

Needle Localization During Prostate Brachytherapy Using Power Doppler Ultrasound

Start date: April 1, 2019
Phase: N/A
Study type: Interventional

This study involves patients who are scheduled for standard care brachytherapy of focal tumours within the prostate, which is normally performed under standard 2-dimensional (2D) ultrasound guidance. The purpose of this study is the acquire power Doppler ultrasound while using a simple oscillator in physical contact with the end of a brachytherapy needle. The vibrations along the needle should be visible in the power Doppler ultrasound, helping to visualize the needle position within the anatomy.

NCT ID: NCT03857113 Not yet recruiting - Prostate Cancer Clinical Trials

Technetium Based Radioguided Surgery for Prostate Cancer (TRACE) Study

TRACE
Start date: March 1, 2019
Phase:
Study type: Observational

PSMA-radioguided surgery

NCT ID: NCT03845751 Not yet recruiting - Prostate Cancer Clinical Trials

HIFU Hemi-ablation Combined With Short-term Androgen Deprivation Therapy for Localized Prostate Cancer.

ENHANCE
Start date: May 1, 2019
Phase: Phase 2
Study type: Interventional

The current study aims to examine the hypothesis that combining the focal effects of HIFU with the systemic effects of androgen deprivation therapy might eradicate the prostatic cancer cells by targeting the 'visible' index focus (by HIFU) and the tumour surrounding microenvironment which may contain 'invisible' foci and aberrant PCa related signalling (by androgen deprivation therapy) to enhance oncological outcomes of HIFU hemi-ablation in men with localized PCa, and consequently reducing treatment failures.

NCT ID: NCT03840200 Not yet recruiting - Breast Cancer Clinical Trials

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

Start date: March 22, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a study in participants with advanced breast, ovarian, or prostate cancer to investigate the dose, safety, pharmacokinetics, and preliminary efficacy of ipatasertib in combination with rucaparib. The study consists of two parts: a Dose-Escalation Phase (Part 1) in participants with previously treated advanced breast cancer, ovarian cancer, or prostate cancer and a Dose-Expansion Phase (Part 2) in participants with advanced prostate cancer who have had at least one line of prior therapy with second-generation androgen-receptor (AR)-targeted agents (e.g., abiraterone, enzalutamide, apalutamide).

NCT ID: NCT03837353 Not yet recruiting - Prostate Cancer Clinical Trials

A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1

Start date: March 30, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a non-randomized multi-center Phase 1b/2a dose escalation and dose expansion study involving 85-97 patients testing DKN-01 as monotherapy or in combination with docetaxel in metastatic castration-resistant prostate cancer. Patients need to be biomarker positive (Dickkopf-1 [DKK1]) either in plasma or biopsy. Other biopsies for correlative studies are encouraged but not mandatory. Pharmacokinetic (PK) testing of one pre-treatment blood sample and one post-treatment blood sample will be mandatory on Day 1 of every cycle.

NCT ID: NCT03836196 Not yet recruiting - Prostate Cancer Clinical Trials

Optimizing Prostate Cancer Treatment in Men With Advanced Local Disease

OPTiMAL
Start date: February 2019
Phase: N/A
Study type: Interventional

Multi-modality therapy that includes a brachytherapy implant improves outcomes in locally advanced prostate cancer when compared to other radiation-based treatments, but is also associated with more adverse side effects. The goal of the OPTiMAL trial is to reduce these side effects by using advanced imaging and biopsy techniques to locate cancer and deliver precision radiation therapy, while not compromising the unprecedented high cure rates obtained for the brachytherapy arm of the Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (ASCENDE-RT) randomized control trial. Additionally, some applied research in genetics, pathology and medical imaging is included. Novel medical imaging methods, namely, multi-parametric magnetic resonance imaging (MRI), multi-parametric trans-rectal ultrasound (TRUS), prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) are used for re-staging of prostate cancer. This is followed by trans-perineal biopsy to locate cancerous areas of the prostate with greater precision compared to conventional biopsy. Results from imaging are compared to those from biopsy to develop image-based cancer detection methods.